Product image of Icatibant Avansor (Icatibant) supplied by GNH India

Icatibant Avansor

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Avansor (Icatibant)

Icatibant, the active ingredient in Icatibant Avansor, is a bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous administration. It is indicated for the treatment of acute hereditary angioedema attacks in patients who have a C1‑inhibitor deficiency, reducing swelling and pain associated with the condition.

GNH India supplies Icatibant Avansor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialty therapy. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Manufacturer / TM Owner

Avansor Pharma Oy

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

  • Hereditary angioedema type I (C1‑inhibitor deficiency): rapidly reduces swelling during acute attacks.
  • Hereditary angioedema type II (functional C1‑inhibitor deficiency): provides prompt symptom relief.
  • Laryngeal edema associated with hereditary angioedema: helps prevent airway obstruction during an acute episode.

How It Works

  • Icatibant competitively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. By inhibiting this pathway, the drug curtails the plasma‑extravasation and tissue swelling that characterize acute hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

  • Injection site pain: discomfort at the subcutaneous injection site.
  • Redness or swelling at injection site: localized erythema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Dizziness: transient sensation of light‑headedness.
  • Flushing: temporary warmth or redness of the skin.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
  • Severe injection‑site necrosis: tissue damage requiring medical attention.
  • Paradoxical angioedema: worsening swelling despite therapy.
  • Hypotension: marked drop in blood pressure.
  • Severe abdominal pain: may indicate visceral edema.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Renal impairment: monitor renal function as the drug is primarily excreted unchanged.
  • Hepatic impairment: use with caution; limited data in severe liver disease.
  • Pregnancy: safety not established; weigh potential benefits against unknown risks.
  • Concomitant ACE inhibitors: may increase bradykinin levels and risk of angioedema.
  • Pediatric use: not studied in children; avoid unless specifically prescribed.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medications that affect bradykinin pathways or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: additive bradykinin effect may exacerbate angioedema.
  • Angiotensin receptor blockers (ARBs): similar risk of increased bradykinin activity.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may increase gastrointestinal irritation.
  • Estrogen‑containing contraceptives: can worsen hereditary angioedema severity.
  • Diuretics: monitor blood pressure and electrolyte balance during therapy.

Frequently Asked Questions

Icatibant Avansor is used to treat acute attacks of hereditary angioedema in patients with a C1‑inhibitor deficiency. By blocking the bradykinin B2 receptor, it helps reduce swelling, pain, and the risk of airway obstruction during an episode.

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By preventing bradykinin from binding, it stops the cascade that leads to vasodilation and increased vascular permeability, thereby limiting the swelling that characterises hereditary angioedema attacks.

The dose of Icatibant Avansor is determined by the prescribing clinician based on the patient’s condition, weight, and severity of the attack. The medication is administered as a subcutaneous injection, and the exact regimen should follow the prescriber’s instructions.

Safety of icatibant in pregnancy and lactation has not been established. Healthcare providers should evaluate the potential benefits against any unknown risks before prescribing it to pregnant or nursing women.

To order Icatibant Avansor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other therapies such as C1‑inhibitor concentrates replace the deficient protein. Icatibant provides rapid symptom relief through a different mechanism and is administered subcutaneously, offering an alternative for patients who may not respond to or tolerate protein‑based therapies.

Icatibant Avansor should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability and potency.

The medication is supplied as a sterile solution for injection and is given subcutaneously, typically into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient following the prescriber’s dosing instructions.

Serious risks include hypersensitivity reactions such as anaphylaxis, paradoxical worsening of angioedema, severe injection‑site necrosis, and hypotension. Patients should be monitored closely after administration, and any signs of severe reaction require immediate medical attention.

Icatibant should be avoided in individuals with known hypersensitivity to icatibant or any component of the formulation. Caution is also advised for patients receiving ACE inhibitors or ARBs due to the increased risk of angioedema, and it is not recommended for children unless specifically prescribed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT